Commentary: Overhyped Alzheimer’s treatments betrayed patients’ hopes. Here’s how science should change
America’s science policies are changing. America’s scientists need to change with them. The recent controversies over the Food and Drug Administration’s accelerated approval of an Alzheimer’s treatment are a lesson in the costs of failing to do so.
Los Angeles Times ·